Merck protease inhibitor MK-639 -- trial cities announced. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023. NLM AIDSLINE Important note: Information in this article was accurate in 1995. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Merck protease inhibitor MK-639 -- trial cities announced. Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5023.

AIDS Treat News. 1995 Apr 7;(no 220):1-2. Unique Identifier : AIDSLINE AIDS/95700338

Abstract: Merck will conduct two large trials to test MK-639, a protease inhibitor. One trial is for people who have never taken AZT or other antiretrovirals, and the other is for those who have used AZT. These trials will be conducted in numerous cities across the United States, with other trials to be conducted in foreign countries. The first trial is seeking 780 people with CD4 counts between 50 and 500; the second trial needs 90 people with CD4 counts between 50 and 400. Contact the Merck Protease Inhibitor Information Line, (800) 379-1332 for information on both trials.
Keywords: Acquired Immunodeficiency Syndrome/*DRUG THERAPY Human HIV Protease Inhibitors/*THERAPEUTIC USE Pyridines/*THERAPEUTIC USE Zidovudine/THERAPEUTIC USE NEWSLETTER ARTICLE RANDOMIZED CONTROLLED TRIAL CLINICAL TRIAL

KWDacquiredimmunodeficiencysyndrome/KWDdrugtherapyhumanhivproteaseinhibitors/KWDtherapeuticusepyridines/KWDtherapeuticusezidovudine/therapeuticusenewsletterarticlerandomizedcontrolledtrialclinicaltrial
951130
M95B0917

Copyright © 1995 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1995. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1995. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .